{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:31:57Z","timestamp":1790742717851,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0009302","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000}}],"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"WHO\/TDR","award":["B80067"],"award-info":[{"award-number":["B80067"]}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["208378\/Z\/17\/Z"],"award-info":[{"award-number":["208378\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Despite a historical association with poor tolerability, a comprehensive review on safety of antileishmanial chemotherapies is lacking. We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported serious adverse events (SAEs).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>For this updated systematic review, we searched the following databases from 1<jats:sup>st<\/jats:sup> Jan 2016 through 2<jats:sup>nd<\/jats:sup> of May 2019: PUBMED, Embase, Scopus, Web of Science, Cochrane, clinicaltrials.gov, WHO ICTRP, and the Global Index Medicus. We included randomised and non-randomised interventional studies aimed at assessing therapeutic efficacy and extracted the number of SAEs reported within the first 30 days of treatment initiation. The incidence rate of death (IRD) from individual treatment arms were combined in a meta-analysis using random effects Poisson regression.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>We identified 157 published studies enrolling 35,376 patients in 347 treatment arms. Pentavalent antimony was administered in 74 (21.3%), multiple-dose liposomal amphotericin B (L-AmB) in 52 (15.0%), amphotericin b deoxycholate in 51 (14.7%), miltefosine in 33 (9.5%), amphotericin b fat\/lipid\/colloid\/cholesterol in 31 (8.9%), and single-dose L-AmB in 17 (4.9%) arms. There was a total of 804 SAEs reported of which 793 (including 428 deaths) were extracted at study arm level (11 SAEs were reported at study level only). During the first 30 days, there were 285 (66.6%) deaths with the overall IRD estimated at 0.068 [95% confidence interval (CI): 0.041\u20130.114; I<jats:sup>2<\/jats:sup> = 81.4%; 95% prediction interval (PI): 0.001\u20132.779] per 1,000 person-days at risk; the rate was 0.628 [95% CI: 0.368\u20131.021; I<jats:sup>2<\/jats:sup> = 82.5%] in Eastern Africa, and 0.041 [95% CI: 0.021\u20130.081; I<jats:sup>2<\/jats:sup> = 68.1%] in the Indian Subcontinent. In 21 study arms which clearly indicated allowing the inclusion of patients with HIV co-infections the IRD was 0.575 [95% CI: 0.244\u20131.355; I<jats:sup>2<\/jats:sup> = 91.9%] compared to 0.043 [95% CI: 0.020\u20130.090; I<jats:sup>2<\/jats:sup> = 62.5%] in 160 arms which excluded HIV co-infections.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Mortality within the first 30 days of VL treatment initiation was a rarely reported event in clinical trials with an overall estimated rate of 0.068 deaths per 1,000 person-days at risk, though it varied across regions and patient populations. These estimates may serve as a benchmark for future trials against which mortality data from prospective and pharmacovigilance studies can be compared. The methodological limitations exposed by our review support the need to assemble individual patient data (IPD) to conduct robust IPD meta-analyses and generate stronger evidence from existing trials to support treatment guidelines and guide future research.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pntd.0009302","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T17:43:30Z","timestamp":1617039810000},"page":"e0009302","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2892-3053","authenticated-orcid":true,"given":"Sauman","family":"Singh-Phulgenda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2158-846X","authenticated-orcid":true,"given":"Prabin","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Ngu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-0109","authenticated-orcid":true,"given":"Brittany J.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3809-372X","authenticated-orcid":true,"given":"Alice","family":"Hawryszkiewycz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8657-9639","authenticated-orcid":true,"given":"Sumayyah","family":"Rashan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-7371","authenticated-orcid":true,"given":"Matthew","family":"Brack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Halleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6213-5224","authenticated-orcid":true,"given":"Fabiana","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1713-6209","authenticated-orcid":true,"given":"Kasia","family":"Stepniewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1426-3680","authenticated-orcid":true,"given":"Piero L","family":"Olliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6008-2963","authenticated-orcid":true,"given":"Philippe J.","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"pntd.0009302.ref001","unstructured":"WHO. Leishmaniasis: Key facts. In: WHO [Internet]. 2020 [cited 5 Jul 2020]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis"},{"key":"pntd.0009302.ref002","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"S Burza","year":"2018","journal-title":"Lancet"},{"key":"pntd.0009302.ref003","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Causes of Death Collaborators","year":"2018","journal-title":"Lancet"},{"key":"pntd.0009302.ref004","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0065-308X(05)61006-8","article-title":"Chemotherapy in the Treatment and Control of Leishmaniasis","volume":"61","author":"J Alvar","year":"2006","journal-title":"Adv Parasitol"},{"key":"pntd.0009302.ref005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4269\/ajtmh.1923.s1-3.307","article-title":"Kala Azar in the Sudan with special reference to its treatment by Tartar Emetic","volume":"s1-3","author":"RG Archibald","year":"1923","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0009302.ref006","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4269\/ajtmh.1985.34.702","article-title":"Electrocardiographic changes during treatment of Leishmaniasis with pentavalent antimony (sodium stibogluconate)","volume":"34","author":"JD Chulay","year":"1985","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0009302.ref007","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/0035-9203(86)90178-1","article-title":"Harmful effect of high stibogluconate treatment of kala-azar in India","volume":"80","author":"C Thakur","year":"1986","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0009302.ref008","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0022-0736(97)80023-4","article-title":"Pentavalent Antimonial-induced Torsade de Pointes","volume":"30","author":"M Ortega-Carnicer","year":"1997","journal-title":"J Electrocardiotogy"},{"key":"pntd.0009302.ref009","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14656566.2015.973850","article-title":"An Update on Pharmacotherapy for Leishmaniasis","volume":"16","author":"S Sundar","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"pntd.0009302.ref010","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4269\/ajtmh.2005.73.871","article-title":"A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya","volume":"73","author":"MK Wasunna","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0009302.ref011","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.4269\/ajtmh.2005.73.1005","article-title":"A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India","volume":"73","author":"TK Jha","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0009302.ref012","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/0974-777X.62886","article-title":"Liposomal amphotericin B and leishmaniasis: Dose and response","volume":"2","author":"S Sundar","year":"2010","journal-title":"J Glob Infect Dis"},{"key":"pntd.0009302.ref013","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.pt.2005.08.026","article-title":"Chemotherapy of trypanosomiases and leishmaniasis","volume":"21","author":"SL Croft","year":"2005","journal-title":"Trends Parasitol"},{"key":"pntd.0009302.ref014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40249-016-0112-2","article-title":"Current challenges in treatment options for visceral leishmaniasis in India: A public health perspective","volume":"5","author":"OP Singh","year":"2016","journal-title":"Infect Dis Poverty"},{"key":"pntd.0009302.ref015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0006988","article-title":"A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia","volume":"13","author":"E Diro","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009302.ref016","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1016\/S1473-3099(16)30140-2","article-title":"Elimination of visceral leishmaniasis on the Indian subcontinent","volume":"16","author":"OP Singh","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"pntd.0009302.ref017","unstructured":"National Vector Borne Disease Control Programme. Operational guidelines on kala-azar (visceral leishmaniasis) elimination in India\u20142015. In: WHO [Internet]. 2015 [cited 29 Oct 2019]. https:\/\/www.who.int\/leishmaniasis\/burden\/Operational_guidelines_on_kala_azar_elimination_in_India.pdf"},{"key":"pntd.0009302.ref018","article-title":"Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives","author":"F Alves","year":"2018","journal-title":"Clinical microbiology reviews"},{"key":"pntd.0009302.ref019","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4269\/ajtmh.2011.10-0321","article-title":"Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia","volume":"84","author":"MO Harhay","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0009302.ref020","doi-asserted-by":"crossref","first-page":"e0009204","DOI":"10.1371\/journal.pntd.0009204","article-title":"Gender disparity in patients enrolled in clinical trials of VL: a systematic review and meta-analysis","volume":"15","author":"P Dahal","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009302.ref021","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1371\/journal.pntd.0002875","article-title":"High Parasitological Failure Rate of Visceral Leishmaniasis to Sodium Stibogluconate among HIV Co-infected Adults in Ethiopia","volume":"8","author":"E Diro","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009302.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0006527","article-title":"The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study","volume":"12","author":"C Abongomera","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009302.ref023","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40261-016-0481-0","article-title":"Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme","volume":"37","author":"R Kimutai","year":"2017","journal-title":"Clin Drug Investig"},{"key":"pntd.0009302.ref024","doi-asserted-by":"crossref","first-page":"e0006830","DOI":"10.1371\/journal.pntd.0006830","article-title":"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India","volume":"12","author":"V Goyal","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009302.ref025","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Reprint\u2014preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"key":"pntd.0009302.ref026","first-page":"1","article-title":"Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform","volume":"11","author":"JT Bush","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009302.ref027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1001026","article-title":"Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological Overview","volume":"8","author":"S Golder","year":"2011","journal-title":"PLoS Med"},{"key":"pntd.0009302.ref028","unstructured":"Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia.: www.covidence.org; 2019."},{"key":"pntd.0009302.ref029","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"PA Harris","year":"2009","journal-title":"J Biomed Inf"},{"key":"pntd.0009302.ref030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-015-0031-0","article-title":"Meta-analysis of incidence rate data in the presence of zero events","volume":"15","author":"MJ Spittal","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"pntd.0009302.ref031","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"JPT Higgins","year":"2002","journal-title":"Stat Med"},{"key":"pntd.0009302.ref032","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/sim.7140","article-title":"Random effects meta-analysis: Coverage performance of 95% confidence and prediction intervals following REML estimation","volume":"36","author":"C Partlett","year":"2017","journal-title":"Stat Med"},{"key":"pntd.0009302.ref033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2008.12.002","article-title":"Empirical evaluation showed that the Copas selection model provided a useful summary in 80% of meta-analyses","volume":"62","author":"JR Carpenter","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"pntd.0009302.ref034","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jclinepi.2009.05.008","article-title":"Empirical evaluation suggests Copas selection model preferable to trim-and-fill method for selection bias in meta-analysis","volume":"63","author":"G Schwarzer","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"pntd.0009302.ref035","first-page":"1","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"JA Sterne","year":"2016","journal-title":"BMJ"},{"key":"pntd.0009302.ref036","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2018"},{"key":"pntd.0009302.ref037","first-page":"25","article-title":"Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries","volume":"76","author":"JD Berman","year":"1998","journal-title":"Bull World Health Organ"},{"key":"pntd.0009302.ref038","first-page":"33","article-title":"A study on efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in a tertiary care centre in eastern bihar","volume":"9","author":"KK Sinha","year":"2019","journal-title":"Indian J Appl Res"},{"key":"pntd.0009302.ref039","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/j.1365-3156.2008.02128.x","article-title":"Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar","volume":"13","author":"S Sundar","year":"2008","journal-title":"Trop Med Int Heal"},{"key":"pntd.0009302.ref040","unstructured":"FDA. (amphotericin B) liposome for injection. 2012 [cited 9 Mar 2020]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/050740s021lbl.pdf"},{"key":"pntd.0009302.ref041","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1371\/journal.pntd.0002916","article-title":"Visceral Leishmaniasis as an AIDS Defining Condition: Towards Consistency across WHO Guidelines","volume":"8","author":"J van Griensven","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009302.ref042","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01943","article-title":"Immunomodulatory therapy of visceral leishmaniasis in human immunodeficiency virus-coinfected patients","volume":"8","author":"W Adriaensen","year":"2018","journal-title":"Front Immunol"},{"key":"pntd.0009302.ref043","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/sim.3964","article-title":"Meta-analysis for rare events","volume":"29","author":"T Cai","year":"2010","journal-title":"Stat Med"},{"issue":"4","key":"pntd.0009302.ref044","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/bimj.201400184","article-title":"Meta-Analysis of Clinical Trials with Rare Events","volume":"57","author":"D Bohning","year":"2015","journal-title":"Biom J"},{"key":"pntd.0009302.ref045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0962280211432218","article-title":"Meta-analysis of incidence of rare events","volume":"22","author":"PW Lane","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"pntd.0009302.ref046","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"MJ Sweeting","year":"2004","journal-title":"Stat Med"},{"key":"pntd.0009302.ref047","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jclinepi.2018.12.007","article-title":"More than one-third of systematic reviews did not fully report the adverse events outcome","volume":"108","author":"R Parsons","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"pntd.0009302.ref048","unstructured":"https:\/\/www.meddra.org\/. Medical Dictionary for regulartory activities. [cited 3 Sep 2020]."},{"key":"pntd.0009302.ref049","unstructured":"National Cancer Institute (U.S. Department of Health and Human Services). Common Terminology Criteria for Adverse Events (CTCAE). [cited 3 Sep 2020]. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0009302","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T21:16:50Z","timestamp":1617916610000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009302"}},"subtitle":[],"editor":[{"given":"David Soeiro","family":"Barbosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009302","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0009302","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,29]]}}}